



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/530,219 07/27/2000		Christof Niehrs	2502498-991150	4031	
35928	7590 12/17/2003		EXAMINER		
GRAY CARY WARE FREDENRICH 1625 MASSACHUSETTS AVENUE, NW			ANDRES, JANET L		
SUITE 300		N YY	ART UNIT	PAPER NUMBER	
WASHINGTO	N, DC 20036-2247		1646		
			DATE MAILED: 12/17/2003	<b>.</b>	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applica	tion No.	Applicant(s)				
Office Action Summary			219	NIEHRS ET AL.				
			er	Art Unit				
			Andres	1646				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
1)	Responsive to communication(s) filed on	n 22 September	2003					
2a)⊠	This action is <b>FINAL</b> . 2b) This action is non-final.							
Disposition of Claims								
4)⊠	Claim(s) <u>1-5</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
6)⊠	Claim(s) <u>2 and 4</u> is/are rejected.							
7)🖂	Claim(s) <u>1,3, and 5</u> is/are objected to.							
8)□	8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers								
	The specification is objected to by the Exa							
10) 🗌 🤈	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. §§ 119 and 120								
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.  13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application)								
since a specific reference was included in the first sentence of the specification or in an Application Data Sheet.  37 CFR 1.78.  a) The translation of the foreign language provisional application has been received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.								
Attachment(	(s)							
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948 ation Disclosure Statement(s) (PTO-1449) Paper No		4) Interview Summary (P 5) Notice of Informal Pate 6) Other:	TO-413) Paper No(s) ent Application (PTO-152)	_·			

Art Unit: 1646

#### RESPONSE TO AMENDMENT

1. Applicant's amendment filed 22 September 2003 is acknowledged. Claims 1-5 are pending and under examination in this application. The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior office action.

#### Claim Rejections/Objections Withdrawn

- 2. The objection to the specification is withdrawn in response to Applicant's amendment including sequence identifiers.
- 3. The objection to claims 1-5 and 7 as referring to figures is withdrawn in response to Applicant's amendment incorporating sequence identifiers and cancellation of claim 7.
- 4. The rejection of claim 1 under 35 U.S.C. 101 as being drawn to non-statutory subject matter is withdrawn in response to Applicant's amendment requiring that the protein be isolated. The rejection of claim 3 under 35 U.S.C. 101 as being drawn to non-statutory subject matter is withdrawn because the expression plasmid is an article of manufacture. The rejection of claim 7 under 35 U.S.C. 101 as being drawn to non-statutory subject matter because it recites a use is withdrawn in response to Applicant's cancellation of this claim.
- 5. The rejection of claim 7 under 35 U.S.C. 112, first paragraph, as lacking enablement is withdrawn in response to Applicant's cancellation of this claim.
- 6. The rejection of claim 7 under 35 U.S.C. 112, second paragraph, as indefinite in merely reciting a use is withdrawn in response to Applicant's cancellation of this claim.

## Claim Objections/Rejections Maintained

7. The objection to claim 1 is maintained. Applicant has rephrased the claim, but as written the phrasing is still awkward and possibly subject to misinterpretation. Language such as "or by a DNA related due to the degeneracy of the genetic code" is suggested.

8. The rejection of claims 2 and 4 under 35 U.S.C. 101 is maintained for reasons of record in the office action of 19 May 2003.

Applicant's amendment to claim 1 is insufficient to overcome this rejection. There is nothing in the claims that requires that the DNA or the cells be isolated. Thus the DNA is not an item of manufacture. Since the cells need not be isolated, they encompass transgenic humans, which are non-statutory subject matter.

### Allowable Subject Matter

9. Claims 3 and 5 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

CLAIMS 1, 3 AND 5 ARE OBJECTED TO. CLAIMS 2 AND 4 ARE REJECTED.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after

Application/Control Number: 09/530,219

Art Unit: 1646

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet Andres, Ph.D., whose telephone number is (703) 305-0557. The examiner can normally be reached on Monday through Friday from 8:00 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564. The fax phone number for this group is (703) 872-9306 or (703) 872-9307 for after final communications.

Communications via internet mail regarding this application, other than those under U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov].

All Internet email communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark Office on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Page 5

Janet Andres, Ph.D. December 11, 2003

ANT PANDRES